Animal Vaccines Market Size
Expected to reach USD 7.9 billion in 2020 and rising at a CAGR of more than 5.8%, animal vaccines market size Growing frequency of foodborne and zoonotic infections is expected to drive market expansion in next years. Long-term market benefits will come from increasing research and development efforts for producing economical, efficient, reasonably priced, high-quality vaccinations for companion and farm animals.
To get key market trends
On the other hand, poor infrastructure and resources for the development of vaccinations as well as low pet healthcare spending in developing nations could hinder the growth of the animal vaccines market. Lack of a comprehensive strategy to guarantee vaccination availability in developing nations results in growing disparity and animal disease load. The OECD Development Co-operation Report 2020 also underlined the lack of clinical infrastructure, particular manufacturing techniques, and more significantly, the financial resources in the developing countries. Furthermore controlling veterinary biologics products including animal vaccinations is the Center for Veterinary Biologics (CVB) of the Animal and Plant Health Inspection Service. Veterinary biologics for their use in the treatment and prevention of animal diseases are guaranteed to be pure, safe, potent, and effective by this control. In line with the technical criteria specified in Annex 1, Title II, to Directive 2001/82/EC, as modified by Directive 2009/9/EC, and the European Pharmacopoeia (Ph. Eur.), the European Medicines Agency (EMA) also keeps an eye on the development and commercialization process of animal vaccines per technical standards. Every commercially sold animal vaccination must satisfy strict technical criteria and go through a rigorous regulatory review.
Unmatched public health disaster, the COVID-19 epidemic has produced hitherto unheard-of and massive disturbances to the world economy influencing several industrial sectors. By means of touch or aerosol transmission, the coronavirus moves from one animal to another, therefore infecting other animals. Reports of many events involving COVID-19 infection in animals have surfaced. Late 2020 saw reports of COVID-19-infected farmed minks in Denmark, Spain, the United States, Italy, and France among others. Therefore, the foregoing advancements have promised notable expenditure on animal health that is further predicted to increase the commercial potential. Rising COVID-19 infection rates in domestic and wild captive animals will force the acceptance of animal vaccinations for guaranteeing preventative animal health, so accelerating the industry development.
Apart from that, various companies are funding the creation of animal vaccinations against COVID-19. For minks and companion animals, for example, Zoetis is working on a vaccination. Launched in Russia, the Carnivak-Cov animal vaccination meant to stop the spread of SARS-CoV-2 in animals including dogs, cats, and minks is reported in the Veterinary and Life Journal of the Russian Federal Veterinary and Phytosanitary in March 2021. The market for animal vaccinations is likely to gain from government help in addressing the increasing infection rates in animals.
Aiming to hasten the vaccination development for cattle and stop the spread of viral infections such coronavirus, the UK government declared the opening of the UK Animal Vaccine Manufacturing and Innovation Center in Surrey. Consequently, government backing, research projects embraced by the commercial companies, and growing COVID-19 infection instances in animals will help the sector to expand much further.
| Report Attribute | Details |
|---|---|
| Base Year | 2020 |
| Animal Vaccines Market Size in 2020 | 7,865.2 Million (USD) |
| Forecast Period | 2021 to 2027 |
| Forecast Period 2021 to 2027 CAGR | 5.8% |
| 2027 Value Projection | 11,569.0 Million (USD) |
| Historical Data for | 2016 to 2020 |
| No. of Pages | 210 |
| Tables, Charts & Figures | 399 |
| Segments covered | Animal type, Technology, Infections, Route of administration, and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
What are the growth opportunities in this market?
Growing pet adoption is slated to amplify the business growth
Adoption of companion animals has sharply risen recently. Considered as members of the family and ideal friends for elderly people are pets. Rising pet adoption will raise demand for animal vaccines, hence driving the evolution of the industry. The start of the COVID-19 epidemic caused dramatic rises in pet adoption rates. The Shelter Animals Count statistics show that, with about 26,000 more pet adoptions than in 2019, the number of pet adoptions in the United States jumped dramatically in 2020. According to the COVID-19 Impact Report, compared to 2019 the national pet adoption rate jumped 34% in 2020. Italy also saw a similar trend in 2020, with about 3.5 million Italians supposedly picking a pet following the initial lockdown.
Animal Vaccines Market Analysis
The farm animal vaccines market was valued at USD 5.49 billion in 2020 led by the increasing prevalence of zoonoses among farm animals. Several zoonoses such as leptospirosis, Johne’s Diseases (JD), viral respiratory tract infections, bovine ephemeral fever, and infectious bovine rhinotracheitis (IBR) among others affect farm animals worldwide and increase the disease burden. Rising prevalence of these conditions is predicted to augment the demand for animal vaccines, thereby stimulating the industry progression during the forecast timeframe.
The live attenuated vaccines segment accounted for around 44% of the market share in 2020 impelled by the high clinical efficacy as compared to inactivated vaccines. Majority of the commercially available veterinary vaccines are live attenuated vaccines. These vaccines are capable of inducing humoral as well as cell-mediated immune responses, thereby offering long-term effectivity. These vaccines are also known to induce higher immunogenicity and often, a single vaccine dose is sufficient to provide long-term protection. Live attenuated vaccines are highly preferred in emerging economies owing to high cost-effectivity as compared to other vaccines.
The viral vaccines segment will reach USD 6.34 billion by 2027 due to the growing prevalence of viral infections globally. The rising demand for meat has led to intense production, with livestock farms housing animals in high densities that prove conducive to rapid pathogen transmission and result in endemic infectious diseases. According to the World Organization for Animal Health (OIE), from 2016 to 2020, notable increase in African swine fever (ASF) outbreaks were reported in African, European, and Asian region. The viral disease was present in 60 countries and accounted for 8,202,702 swine deaths. In the first five months of 2021, the authorities in Poland reported an exponential 520% increase in ASF outbreaks in domestic pig herds. The constant threat posed by the endemic and emerging viral disease has led to the development of viral vaccines offering clinical effectiveness.
Learn more about the key segments shaping this market
USD 4.57 billion in the injectable vaccinations industry projected for 2020. In animals, intramuscular or subcutaneous is the main method of vaccination; it is therefore given first priority for diseases needing systemic protection. This method lowers possible adverse responses at the injection site and maximizes the vaccination immunogenicity. Many clinical trials have shown the immunological advantage of injectable vaccinations with few local adverse effects. Giving a vaccination by injection also guarantees the right dose. Clinical efficacy has been driven by the creation of new mRNA vaccines delivered intramuscularly. According to several studies, injections of vaccinations provide greater efficiency and strong humoral and cellular immune responses together with a somewhat lengthy duration of impact.
Learn more about the key segments shaping this market
U.S. dominated the North America animal vaccines market and will cross USD 4.20 billion by 2027 on account of the several factors such as growing acceptance of pets, high pet care expenditure, and a rise in the incidence of zoonotic diseases across the country. According to the American Pet Products Association's 2017-2018 National Pet Owners Survey, there were more than 89 million pet dogs and 94 million pet cats in the U.S. households. The veterinary care expenditure surged from USD 48.35 billion in 2010 to USD 75.38 billion in 2019 and is unparalleled as compared to the other countries. The growing pet adoption and high pet care expenditure are set to increase the demand for animal vaccines, further facilitating the industry revenue.
Animal Vaccines Market Share
Some of the major companies operating in the market are
- Ceva Sante Animale
- Boehringer Ingelheim Animal Health
- Dechra Pharmaceuticals
- Elanco Animal Health
- Merck Animal Health
- Hipra Animal Health Limited
- Zoetis
- Neogen Corporation
These major leaders emphasize on adopting strategic formulations such as research collaborations, vertical integration, new product development & commercialization for business expansion. Furthermore, these participants are expanding their geographical presence to untapped geographies that allows them to enter new markets and garner maximum revenue share.
Animal vaccines market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments
Click here to Buy Section of this Report
Market, By Animal type, 2016 - 2027 (USD Million)
- Farm Animal Vaccines
- Poultry Vaccines
- Cattle Vaccines
- Swine Vaccines
- Equine Vaccines
- Aquaculture Vaccines
- Companion Animal Vaccines
- Dog Vaccines
- Cat Vaccines
Market, By Technology, 2016 - 2027 (USD Million)
- Live Attenuated Vaccines
- Inactivated Vaccines
- Toxoid Vaccines
- Recombinant Vaccines
- Other Vaccines
Market, By Infections, 2016 - 2027 (USD Million)
- Bacterial Vaccines
- Viral Vaccines
- Parasitic Vaccines
- Fungal Vaccines
- Others
Market, By Route of Administration, 2016 - 2027 (USD Million)
- Injection Vaccines
- Oral Vaccines
- Immersion/Spray Vaccines
- Others
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Poland
- Netherlands
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Taiwan
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- South Africa
- GCC Countries
- Israel
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy